TERAVOLT Publishes New Study on Impact of Covid-19 on Thoracic Malignancies

New Research Suggests That Healthcare System Must Make Critical Changes in Current Treatment Models to Help Treat Lung Cancer Patients with Covid-19

NASHVILLE, TN and MILAN, June 12, 2020 – The Thoracic Cancers International COVID 19 Collaboration (TERAVOLT) announced today the findings of a recent cohort study exploring outcomes of COVID-19 patients with thoracic cancer. The results from the study were published today in The Lancet Oncology and suggest a high hospital admission rate and higher mortality rate for these patients—suggesting there is significant room for improvement in the treatment of these vulnerable patients during the pandemic.

Thoracic malignancy refers to lung cancers, lung carcinoid tumors, thymic malignancies, and mesothelioma. There are more than 2 million cases globally of these cancers every year. Recently the American Cancer Society reported on a reduction in cancer mortality over the last few years and this was thought to be improvements in treatment options for patients with lung cancer.

For the study, TERAVOLT studied 200 patients from eight countries between the periods of March 26, 2020 and April 15, 2020. Of the 200 patients with COVID-19 studied, 76% of patients were hospitalized and 33% died, with a majority of the 147 patients who met criterial for intensive care unit (ICU) admission not being admitted to the ICU. The study shows the mortality rates of COVID-19 in thoracic cancer patients to be higher than any other kind of cancer patients.

“There are some critical outcomes of this study that the medical community must pay serious attention to,” said Dr. Marina Garassino, Chief of the Thoracic Oncology Unit at Istituto Nazionale dei Tumori Cancer Institute in Milan and Chief Investigator of Research for TERAVOLT. “Most importantly, we must look at what is keeping these patients out of ICU and whether physician or institution-based biased plays a role.”

Dr. Leora Horn, Clinical Director of the Thoracic Oncology Program at Vanderbilt University and Co-founder of TERAVOLT, agrees. “We must not stop treating our thoracic patients during this time, we need to continue to be aggressive of treatment with them during COVID-19.”

Some other takeaways from the organization and the report include:

  • Trying to keep these patients out of hospitals for routine visits or treatments as much as possible by using mor telehealth and in-home resources
  • Lung cancer patients should not be excluded from ICU beds and given the same opportunities for a priority treatment as other patients
  • Teravolt demonstrates unprecedented collaboration among international experts to deal with the sensitive nature of Lung Cancer patients during COVID-19
  • Lung cancer is the number one cancer killer and their needs must be addressed with a sense of urgency

The TERAVOLT study can be found on thelancet.com as of June 12, 2020.

The Thoracic Cancers International COVID 19 Collaboration, also known as TERAVOLT, is an international consortium that was created to understand the impact of COVID-19 on patients with thoracic malignancies. Made up of medical experts from leading institutions around the world, the organization aims to identify and understand risk factors associated with morbidity and mortality in patients with thoracic malignancies who are infected with COVID-19 as well as determine therapies that may impact patient survival. TERAVOLT also provides collaborators and the global medical community with guidance on the management of patients with thoracic malignancies during the COVID-19 pandemic. To learn more about TERAVOLT, visit www.terravolt-consortium.org

Media Contact:
Juliet Shavit
SmartMark Communications, LLC for TERAVOLT

Lung Cancer News Spotlights Teravolt

We are facing a global pandemic with COVID-19 and our patients with thoracic malignancies are particularly susceptible. We have formed a global consortium TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion) registry for thoracic cancers)

The goal of this consortium is to gather information on patients with thoracic cancer patients infected with COVID-19. We recognize there are other registries opening specifically for patients on checkpoint inhibitor therapy as well as other tumor types. This registry is designed to capture patients with thoracic malignancies regardless of therapies administered.

We hope to provide you with real time data on therapies that are effective in treating our patients who are infected with COVID-19 as well as answer important questions identifying risk factors for developing COVID-19 and what happens to patients where therapy is delayed.

We currently have 62 investigators from countries worldwide who are participating in this important initiative. We would like to invite you to participate as well.

If you decide to participate we will provide you with a center ID for which you can enter all de-identified patient data. We will provide you with a protocol template for which you can obtain local IRB approval. LOCAL IRB APPROVAL IS REQUIRED BEFORE DATA ENTRY FOR YOUR SITE COULD BEGIN.

We hope you will consider joining us. If interested please contact Leora Horn at leora.horn@vumc.org or Jennifer Whisenant at j.whisenant@vumc.org or Marina Garassino at Marina.Garassino@istitutotumori.mi.it